SOLENO THERAPEUTICS INC (SLNO) Q3 2025 10-Q Quarterly Report
SOLENO THERAPEUTICS INC (SLNO) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
SOLENO THERAPEUTICS INC Q3 2025 10-Q Analysis
Risk Factors
- • Newly added risk: FDA approval of VYKAT XR on March 26, 2025 triggered commercialization challenges and operating expense increases
- • Materially updated risk: Debt summary updated with $50M outstanding, potential additional $100M availability, floating interest at SOFR +5.50%
SOLENO THERAPEUTICS INC Q3 2025 Quarterly FinancialsXBRL
Revenue
$66M
▲ +102.2% QoQ
Net Income
$26M
▲ +134.0% YoY▲ +652.5% QoQ
Operating Margin
33.5%
▲ +5346bp QoQ
Net Margin
39.4%
▲ +5382bp QoQ
ROE
5.3%
Total Assets
$600M
EPS (Diluted)
$0.55
▲ +128.6% YoY▲ +1200.0% QoQ
Operating Cash Flow
$43M
▲ +391.1% YoY▲ +444.7% QoQ
Source: XBRL data from SOLENO THERAPEUTICS INC Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on SOLENO THERAPEUTICS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.